Q-omics provides the consensus-scored NLN profile across patient tissues and cancer cell-line models. NLN expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NLN is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, NLN protein abundance shows 23,167 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where NLN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLN survival associations across molecular data types. NLN RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLN RNA expression–survival associations across cancer types. High NLN expression shows unfavorable associations in UVM, ACC, BLCA and PAAD, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NLN RNA expression.
This table summarizes NLN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NLN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLN shows higher tumor expression in HNSC, KIRP, BLCA, STAD, LUAD and LUSC. The HNSC box plot shows higher NLN RNA expression in tumor versus normal tissue (log2 FC = +0.831, t-test p < 0.001).
This table shows molecular features associated with NLN in patient tissues and cancer cell lines. In patient samples, NLN shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NLN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
